D-0499-2026 Class II Ongoing

Recalled by SCOPE HEALTH — New York, NY

FDA drug recall D-0499-2026 was initiated by SCOPE HEALTH on Apr 20, 2026 and is designated Class II. Reason for recall: Lack of Assurance of Sterility The recall status is ongoing.

Recall details

Product Type
Drugs
Report Date
May 6, 2026
Initiation Date
Apr 20, 2026
Voluntary/Mandated
Voluntary: Firm initiated

Product description

Optase Dry Eye Intense Drops (Glycerin 0.2%), packaged in 0.33 fl oz, Sterile, Manufactured for Scope Health Inc., 79 Madison Ave., 8th Floor, New York, NY 10016, USA, NDC 72972-002-01.

Reason for recall

Lack of Assurance of Sterility

Distribution pattern

Nationwide within the United States

Code information

Lot#: 8T98, 9T31, 9T32, Exp. Date: 30/04/26; 2V13, 2V14, 2V15, Exp. Date 30/06/26; 3V35, Exp. Date 31/08/26;3V36, 3V37, Exp. Date 30/09/26; 5V45, 5V46, 9V12, Exp. Date 31/03/27; 1X57, 1X70, 1X84, Exp. Date 31/05/27.

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0499-2026
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0499-2026. Report a data issue: hello@regdatalab.com.